Home / CMS Lawyers / Ruth Mahfoozpour
Portrait of Ruth Mahfoozpour

Ruth Mahfoozpour

Attorney-at-Law for Intellectual Property

CMS Reich-Rohrwig Hainz
Rechtsanwälte GmbH
Gauermanngasse 2
1010 Vienna
Languages German, English, French

Ruth Mahfoozpour works as an attorney-at-law primarily in the fields of Intellectual Property (IP) and Unfair Competition, Technology, Media & Telecommunications (TMC), and Life Sciences & Healthcare. She joined CMS Reich-Rohrwig Hainz in 2017 and deals especially with litigious mandates in these areas.

Ruth Mahfoozpour advises companies active in the life sciences, media, and consumer goods industries. She advises on issues relating to pharmaceuticals and medical devices, healthcare services, trade secrets, the advertising/marketing of consumer goods, media services, and trademark rights.

During her legal studies at the University of Vienna, Ruth Mahfoozpour worked at the Institute for Civil Procedure Law and later gained experience as an Associate for Dispute Resolution & Litigation. As part of her IP and unfair competition law practice, she regularly handles cases pending before the courts. Ruth Mahfoozpour completed a master's degree at King’s College London (The Dickson Poon School of Law) in 2018/2019 focusing on IP and arbitration.

more less


Please find the German publications here.

more less


  • 2018 - 2019 – Master’s, King’s College London (The Dickson Poon School of Law), LL.M.
  • 2015 - Intern, WKO Strasbourg
  • 2014 - 2015 – Teaching Assistant, University of Vienna, Institute for Civil Procedure Law
more less


Ad­verse ef­fects of drugs and vac­cines in Aus­tria
1. Drug ad­verse ef­fects: kinds of re­spons­ib­il­ity 1.1 Which are the main kinds of re­spons­ib­il­ity (con­trac­tu­al, in tort, crim­in­al) of the fol­low­ing sub­jects with re­spect to ad­verse drugs re­ac­tions? A...
Aus­tria: What's new in med­ic­al device law?
In Ju­ly 2021, a new Med­ic­al Devices Act (MPG 2021) came in­to force in Aus­tria that sets out new ob­lig­a­tions and re­quire­ments for play­ers in the med­ic­al devices mar­ket. However, it only cov­ers those leg­al...
Vac­cine com­pens­a­tion re­gimes in Aus­tria
1. Are COV­ID-19 vac­cin­a­tions ob­lig­at­ory in your jur­is­dic­tion? Are you ex­pect­ing any le­gis­lat­ive changes to en­able man­dat­ory vac­cines for all or cer­tain people (e.g. health­care pro­fes­sion­als, pub­lic ser­vants...
Keine Produk­thaf­tung für Ge­sund­heit­s­tipps in der Tageszei­tung
Der EuGH hatte sich zu­let­zt mit der Frage zu beschäfti­gen, ob die in ein­er Kolumne ein­er großen ös­ter­reichis­chen Tageszei­tung er­schienen­en Ge­sund­heit­s­tipps ein Produkt darstel­len, für das der Medi­en­in­hab­er...
Di­git­al health apps and telemedi­cine in Aus­tria
Di­git­al Health Apps/Soft­ware 1. How is the soft­ware with­in di­git­al health apps clas­si­fied in your jur­is­dic­tion, and what reg­u­la­tion(s) ap­ply? 1.1 Is it con­sidered a “med­ic­al device” or a “product”...
Man­dat­ory no­ti­fic­a­tion of sup­ply short­ages of pre­scrip­tion medi­cines
As of April 1st, 2020, mar­ket­ing au­thor­iz­a­tion hold­ers must no­ti­fy to the Aus­tri­an Fed­er­al Of­fice for Safety in Health Care (BASG) if pre­scrip­tion medi­cines are not avail­able or only avail­able in lim­ited...
New re­port­ing ob­lig­a­tion for sup­ply short­ages of pre­scrip­tion medi­cines
Since 1 April 2020, if pre­scrip­tion drugs are not avail­able or only avail­able in lim­ited quant­it­ies, mar­ket­ing au­thor­isa­tion hold­ers have had to no­ti­fy the BASG. Since the new reg­u­la­tion came in­to force...